{
    "title": "Individual feed for http://feeds.benzinga.com/benzinga",
    "link": "http://feeds.benzinga.com/benzinga",
    "description": "Individual feed output.",
    "lastBuildDate": "2025-09-11T17:26:44.024027",
    "items": [
        {
            "title": "Bitcoin At A Crossroad: Why You Need To Watch $108,000 And $116,000",
            "link": "https://www.benzinga.com/crypto/cryptocurrency/25/09/47629537/bitcoin-at-a-crossroad-why-you-need-to-watch-108000-and-116000",
            "description": "On-chain data shows that Bitcoin (CRYPTO: BTC ) is holding a crucial support level at $114,000, with markets now at a crossroads that could define its...",
            "pubDate": "2025-09-11T19:42:41",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/09/11/A-Futuristic-Digital-themed-Illustration.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Anglo Teck: A New Copper Empire Is Quietly Taking Shape",
            "link": "https://www.benzinga.com/markets/commodities/25/09/47629466/anglo-teck-a-new-copper-empire-is-quietly-taking-shape",
            "description": "Anglo American's tie-up with Teck could reshape the global commodities map. The merged company will have a strong focus on copper and generate signifi...",
            "pubDate": "2025-09-11T19:39:29",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/09/11/Shanghai--China---March-19--2019-Bales-O.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Oracle's 40% Moonshot Put Defiance's ORCX ETF On The Map",
            "link": "https://www.benzinga.com/etfs/specialty-etfs/25/09/47629173/oracles-40-moonshot-put-defiances-orcx-etf-on-the-map",
            "description": "Defiance CEO Sylvia Jablonski on ORCX's amplified Oracle rally, the risks of leverage, and why single-stock ETFs suit short-term AI trades. read more",
            "pubDate": "2025-09-11T19:25:29",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/09/11/Deerfield---Circa-June-2019-Oracle-Corpo.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Buffett, Ackman, Ives Are Now ETF Brandsâ€”And It's Changing The Game",
            "link": "https://www.benzinga.com/etfs/specialty-etfs/25/09/47629043/buffett-ackman-ives-are-now-etf-brands-and-its-changing-the-game",
            "description": "From Buffett's OMAH to Ackman's ACKY, the rise of personality ETFs is giving investors access to legendary strategies with unique twists. read more",
            "pubDate": "2025-09-11T19:18:33",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/09/11/Clean-Energy-ETFs-In-Focus-As-Trump-Halt.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug",
            "link": "https://www.benzinga.com/analyst-stock-ratings/price-target/25/09/47628962/analysts-raise-price-targets-following-strong-data-from-revolution-medicines-p",
            "description": "Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safe...",
            "pubDate": "2025-09-11T19:14:44",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/09/11/Revolution-Medicines.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        }
    ]
}